Showing 1 - 20 results of 93 for search '"Brain Neoplasms drug therapy"', query time: 1.34s Refine Results
1
Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial

Authors: Thierry Andre, Mayur Amonkar, Josephine M Norquist, Kai-Keen Shiu, Tae Won Kim, Benny Vittrup Jensen, Lars Henrik Jensen, Cornelis J A Punt, Denis Smith, Rocio Garcia-Carbonero, Isabel Sevilla, Christelle De La Fouchardiere, Fernando Rivera, Elena Elez, Luis A Diaz, Takayuki Yoshino, Eric Van Cutsem, Ping Yang, Mohammed Farooqui, Dung T Le

Contributors: Oncology, CCA - Treatment and quality of life

Source: lancet oncology, 22(5), 665-677. Lancet Publishing Group
Andre, T, Amonkar, M, Norquist, J M, Shiu, K-K, Kim, T W, Jensen, B V, Jensen, L H, Punt, C J A, Smith, D, Garcia-Carbonero, R, Sevilla, I, De La Fouchardiere, C, Rivera, F, Elez, E, Diaz, L A, Yoshino, T, Van Cutsem, E, Yang, P, Farooqui, M & Le, D T 2021, ' Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177) : an open-label, randomised, phase 3 trial ', The Lancet Oncology, vol. 22, no. 5, pp. 665-677 . https://doi.org/10.1016/S1470-2045(21)00064-4

Subject Terms: Oncology, Adult, Aged, Antibodies, Monoclonal, Humanized/therapeutic use, Brain Neoplasms/drug therapy, Colorectal Neoplasms/drug therapy, DNA Mismatch Repair, Female, Humans, Male, Microsatellite Instability, Middle Aged, Neoplasm Metastasis, Neoplastic Syndromes, Hereditary/drug therapy, Quality of Life, humanities

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f49da4cb9b41a6e7a1f510c4499b454
https://pure.amc.nl/en/publications/healthrelated-quality-of-life-in-patients-with-microsatellite-instabilityhigh-or-mismatch-repair-deficient-metastatic-colorectal-cancer-treated-with-firstline-pembrolizumab-versus-chemotherapy-keynote177-an-openlabel-randomised-phase-3-trial(68c0f3ec-28fa-4966-a295-8946d25219a7).html

3
MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials

Authors: Hegi, Monika E., Genbrugge, Els, Gorlia, Thierry, Stupp, Roger, Gilbert, Mark R., Chinot, Olivier L., Nabors, L. Burt, Jones, Greg, Van Criekinge, Wim, Straub, Josef, Weller, Michael

Source: Clinical cancer research, vol. 25, no. 6, pp. 1809-1816
Hegi, Monika E; Genbrugge, Els; Gorlia, Thierry; Stupp, Roger; Gilbert, Mark R; Chinot, Olivier Louis; Nabors, Louis Burt; Jones, Greg; van Criekinge, Wim; Straub, Josef; Weller, Michael (2019). MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide. A Pooled Analysis of Four Clinical Trials. Clinical Cancer Research, 25(6):1809-1816.
Clin Cancer Res

Subject Terms: Antineoplastic Agents, Alkylating/pharmacology, Antineoplastic Agents, Alkylating/therapeutic use, Brain Neoplasms/drug therapy, Brain Neoplasms/genetics, Clinical Trials as Topic, DNA Methylation, DNA Modification Methylases/genetics, DNA Repair Enzymes/genetics, Datasets as Topic, Drug Resistance, Neoplasm/genetics, Female, Glioblastoma/drug therapy, Glioblastoma/genetics, Humans, Male, Middle Aged, Patient Selection, Promoter Regions, Genetic/genetics, Reference Values, Temozolomide/pharmacology, Temozolomide/therapeutic use, Tumor Suppressor Proteins/genetics, Cancer Research, Oncology, Standard treatment, Temozolomide, medicine.drug, medicine, Clinical trial, business.industry, business, Randomized controlled trial, law.invention, law, Internal medicine, medicine.medical_specialty, Receiver operating characteristic, Bevacizumab, Cutoff, DNA methylation, Clinic for Neurology, 610 Medicine & health, Article

File Description: application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::541f2a7bb7145dd80385e963d15f4466
https://serval.unil.ch/resource/serval:BIB_F20783904E75.P001/REF.pdf

4
Administration précoce de témozolomide après chirurgie chez des patients ayant un glioblastome de mauvais pronostic: étude de faisabilité

Authors: Florence Lefranc, Niloufar Sadeghi, Sylvie Luce, Elly Chaskis, Daniel Devriendt, Serge Goldman, Olivier De Witte, Christian Melot

Source: Bulletin du cancer, 105 (7-8

Subject Terms: Imagerie médicale, radiologie, tomographie, Hématologie, Cancérologie, Aged, Antineoplastic Agents, Alkylating -- administration & dosage -- adverse effects, Brain Neoplasms -- drug therapy -- surgery, Chemotherapy, Adjuvant, Dacarbazine -- administration & dosage -- adverse effects -- analogs & derivatives, Drug Administration Schedule, Fatigue -- chemically induced, Feasibility Studies, Glioblastoma -- drug therapy -- surgery, Humans, Lymphopenia -- chemically induced, Middle Aged, Nausea -- chemically induced, Neutropenia -- chemically induced, Postoperative Care, Prognosis, Prospective Studies, Temozolomide, Vomiting -- chemically induced, Early adjuvant treatment, Glioblastoma, Toxicity, Cancer Research, Radiology Nuclear Medicine and imaging, Oncology, Hematology, General Medicine, medicine.disease, medicine, business.industry, business, Gynecology, medicine.medical_specialty, Resection, Traitement adjuvant, medicine.drug, Population, education.field_of_study, education

File Description: 1 full-text file(s): application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f705df8606d4d5e07ec2cc8b8835e351
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/277121

5
Targeting integrins in malignant glioma

Authors: Tabatabai, G, Weller, M, Nabors, B, Picard, M, Reardon, D, Mikkelsen, T, Ruegg, C, Stupp, R

Source: Targeted Oncology, vol. 5, no. 3, pp. 175-181
Tabatabai, G; Weller, M; Nabors, B; Picard, M; Reardon, D; Mikkelsen, T; Ruegg, C; Stupp, R (2010). Targeting integrins in malignant glioma. Targeted Oncology, 5(3):175-181.

Subject Terms: Antineoplastic Agents/therapeutic use, Brain Neoplasms/drug therapy, Brain Neoplasms/metabolism, Clinical Trials as Topic, Glioma/drug therapy, Glioma/metabolism, Humans, Integrins/antagonists & inhibitors, Signal Transduction, Clinic for Neurology, 610 Medicine & health

File Description: application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a62fc1fdac7a2956bdd5ead21ab06314
http://doc.rero.ch/record/318237/files/11523_2010_Article_156.pdf

7
Targeting glioma stem-like cell survival and chemoresistance through inhibition of lysine-specific histone demethylase KDM2B

Authors: Kamilla E. Jensen, Kristoffer Vitting-Seerup, Hans Skovgaard Poulsen, Jane Skjøth-Rasmussen, Mette Villingshøj, Henriette Pedersen, Jannick Brennum, Rikke Darling Rasmussen, Signe Regner Michaelsen, Mikkel Staberg, Petra Hamerlik

Source: Staberg, M, Rasmussen, R D, Michaelsen, S R, Pedersen, H, Jensen, K E, Villingshøj, M, Skjoth-Rasmussen, J, Brennum, J, Vitting-Seerup, K, Poulsen, H S & Hamerlik, P 2018, ' Targeting glioma stem-like cell survival and chemoresistance through inhibition of lysine-specific histone demethylase KDM2B ', Molecular Oncology, vol. 12, no. 3, pp. 406-420 . https://doi.org/10.1002/1878-0261.12174
Molecular Oncology, Vol 12, Iss 3, Pp 406-420 (2018)
Molecular Oncology

Subject Terms: Antineoplastic Agents/administration & dosage, Apoptosis/drug effects, Astrocytes/metabolism, Brain Neoplasms/drug therapy, Cell Line, DNA Damage/drug effects, Drug Resistance, Neoplasm, Etoposide/administration & dosage, F-Box Proteins/genetics, Glioblastoma/drug therapy, Histones/metabolism, Humans, Jumonji Domain-Containing Histone Demethylases/genetics, Lomustine/administration & dosage, Lysine/metabolism, Neoplastic Stem Cells/metabolism, Primary Cell Culture, Journal Article, Research Support, Non-U.S. Gov't, Cancer Research, Genetics, Molecular Medicine, General Medicine, Oncology, Histone, biology.protein, biology, Chromatin, Epigenetics, Cancer research, Glioma, medicine.disease, medicine, Cancer, Demethylase, KDM2B, Progenitor cell, cancer stem‐like cell, chemoresistance, epigenetics, glioblastoma, histone demethylase, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, lcsh:RC254-282, Research Article, Research Articles

File Description: application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf53bff8bad4133394dfd6e7ad0716b2
https://curis.ku.dk/portal/da/publications/targeting-glioma-stemlike-cell-survival-and-chemoresistance-through-inhibition-of-lysinespecific-histone-demethylase-kdm2b(9c68af43-b8c8-4f29-a134-2f9520fe950b).html

8
Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter - still a dilemma?

Authors: Hegi, M.E., Stupp, R.

Source: Hegi, Monika E; Stupp, Roger (2015). Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter-still a dilemma? Neuro-Oncology, 17(11):1425-1427.
Neuro-oncology, vol. 17, no. 11, pp. 1425-1427

Subject Terms: Clinic for Oncology and Hematology, 610 Medicine & health, Antineoplastic Agents/therapeutic use, Brain Neoplasms/drug therapy, Brain Neoplasms/genetics, DNA Methylation/genetics, DNA Modification Methylases/genetics, DNA Repair Enzymes/genetics, Dacarbazine/analogs & derivatives, Dacarbazine/therapeutic use, Glioblastoma/drug therapy, Glioblastoma/genetics, Humans, Promoter Regions, Genetic/genetics, Tumor Suppressor Proteins/genetics

File Description: application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8245469ee55a027f14a0dcf5ae4fd0b9
http://doc.rero.ch/record/292743/files/nov198.pdf

9
Targetting αvβ3 and α5β1 integrins with Ecballium elaterium (L.) A. Rich. seed oil

Authors: Imen Touihri-Barakati, Naziha Marrakchi, Belgacem Hanchi, Karim Hosni, Khaoula Khwaldia, Abdennacer Boulila, José Luis, Olfa Kallech-Ziri

Contributors: Laboratoire des Substances Naturelles (LR02INRAP10), Institut National de Recherche et d'Analyse Physico-chimique (INRAP-Tunisie), Faculté de Médecine de Tunis, Université Tunis El Manar (UTM), Laboratoire des Venins et Biomolécules Thérapeutiques - Laboratory of Venoms and Therapeutic Biomolecules (LR11IPT08), Institut Pasteur de Tunis, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Faculté des Sciences de Tunis, Université de Tunis [Tunis], Centre de Recherches en Oncologie biologique et Oncopharmacologie (CRO2), Aix Marseille Université (AMU)- Hôpital de la Timone [CHU - APHM] (TIMONE)-Institut National de la Santé et de la Recherche Médicale (INSERM), This research was supported by Ministry of High Education and Scientific Research of Tunisia (MERST) and the Institut National de la Santé et de la Recherche Médicale (INSERM) and by grants from INCa (Institut National du Cancer) and ARCUS (Action en Région de Coopération Universitaire et Scientifique).

Source: Biomedicine and Pharmacotherapy
Biomedicine and Pharmacotherapy, Elsevier Masson, 2016, 84, pp.1223-1232. ⟨10.1016/j.biopha.2016.10.035⟩

Subject Terms: Adhesion, Angiogenesis, Ecballium elaterium, Glioma cell line, Seed oil, αvβ3 and α5β1 integrins, MESH: Brain Neoplasms/blood supply, MESH: Brain Neoplasms/drug therapy, MESH: Glioma/pathology, MESH: Humans, MESH: Integrin alpha5beta1/metabolism, MESH: Integrin beta3/metabolism, MESH: Neovascularization, Pathologic/drug therapy, MESH: Plant Oils/pharmacology, MESH: Plant Oils/therapeutic use, MESH: Seeds/chemistry, MESH: Time-Lapse Imaging, MESH: Brain Neoplasms/pathology, MESH: Cell Adhesion/drug effects, MESH: Cell Line, Tumor, MESH: Cell Movement/drug effects, MESH: Cell Proliferation/drug effects, MESH: Cucurbitaceae/chemistry, MESH: Glioma/blood supply, MESH: Glioma/drug therapy, [SDV]Life Sciences [q-bio], Pharmacology, General Medicine, biology.organism_classification, biology, Cell growth, Cell adhesion, Elaterium, Cell culture, Biochemistry, Fibronectin, biology.protein, Integrin

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::defb1ac9fb0715fda2d704342ce2bc18
https://hal-riip.archives-ouvertes.fr/pasteur-01966126

10
Targetting alphavbeta3 and alpha5beta1 integrins with Ecballium elaterium (L.) A. Rich. seed oil

Authors: Touihri-Barakati, Imen, Kallech-Ziri, Olfa, Boulila, Abdennacer, Khwaldia, Khaoula, Marrakchi, Naziha, Hanchi, Belgacem, Hosni, Karim, Luis, José

Contributors: Laboratoire des Substances Naturelles (LR02INRAP10), Institut National de Recherche et d'Analyse Physico-chimique [Ariana, Tunisie] (INRAP), Laboratoire des Venins et Biomolécules Thérapeutiques - Laboratory of Venoms and Therapeutic Biomolecules (LR11IPT08), Institut Pasteur de Tunis, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Faculté de Médecine de Tunis, Université de Tunis El Manar (UTM), Faculté des Sciences Mathématiques, Physiques et Naturelles de Tunis (FST), Centre de Recherches en Oncologie biologique et Oncopharmacologie (CRO2), Aix Marseille Université (AMU)- Hôpital de la Timone [CHU - APHM] (TIMONE)-Institut National de la Santé et de la Recherche Médicale (INSERM), This research was supported by Ministry of High Education and Scientific Research of Tunisia (MERST) and the Institut National de la Santé et de la Recherche Médicale (INSERM) and by grants from INCa (Institut National du Cancer) and ARCUS (Action en Région de Coopération Universitaire et Scientifique).

Source: Biomedicine and Pharmacotherapy
Biomedicine and Pharmacotherapy, Elsevier Masson, 2016, 84, pp.1223-1232. ⟨10.1016/j.biopha.2016.10.035⟩

Subject Terms: Glioma cell line, Angiogenesis, Ecballium elaterium, αvβ3 and α5β1 integrins, Adhesion, Seed oil, MESH: Brain Neoplasms/blood supply, MESH: Brain Neoplasms/drug therapy, MESH: Glioma/drug therapy, MESH: Glioma/pathology, MESH: Humans, MESH: Integrin alpha5beta1/metabolism, MESH: Integrin beta3/metabolism, MESH: Neovascularization, Pathologic/drug therapy, MESH: Plant Oils/pharmacology, MESH: Plant Oils/therapeutic use, MESH: Seeds/chemistry, MESH: Time-Lapse Imaging, MESH: Brain Neoplasms/pathology, MESH: Cell Adhesion/drug effects, MESH: Cell Line, Tumor, MESH: Cell Movement/drug effects, MESH: Cell Proliferation/drug effects, MESH: Cucurbitaceae/chemistry, MESH: Glioma/blood supply, [SDV.CAN]Life Sciences [q-bio]/Cancer, [SDV]Life Sciences [q-bio]

Access URL: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::b2a24ef9fdd79fb4993b858c2f218f07
https://hal-amu.archives-ouvertes.fr/hal-01474971

11
Current management of low-grade gliomas

Authors: Brigitta G. Baumert, Monika E. Hegi, Andreas F. Hottinger

Contributors: Radiotherapie, RS: FHML non-thematic output, RS: GROW School for Oncology and Developmental Biology, RS: GROW - R2 - Innovative Cancer Diagnostics & Therapy

Source: Current opinion in neurology, vol. 29, no. 6, pp. 782-788
Europe PubMed Central
Current Opinion in Neurology, 29(6), 782-788. LIPPINCOTT WILLIAMS & WILKINS

Subject Terms: Antineoplastic Agents, Alkylating/therapeutic use, Brain Neoplasms/diagnosis, Brain Neoplasms/drug therapy, Brain Neoplasms/genetics, Brain Neoplasms/therapy, Combined Modality Therapy, Dacarbazine/analogs & derivatives, Dacarbazine/therapeutic use, Disease-Free Survival, Glioma/diagnosis, Glioma/drug therapy, Glioma/genetics, Glioma/therapy, Humans, Mutation, Prognosis, Treatment Outcome, Clinical Neurology, Neurology, Current management, Chemotherapy, medicine.medical_treatment, medicine, Median survival, business.industry, business, Radiation therapy, Surgery, medicine.medical_specialty, Temozolomide, medicine.drug, Disease, Low-Grade Glioma, Pediatrics, chemotherapy, low-grade glioma, management, molecular markers, radiotherapy, surgery

File Description: application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3de7cf3ad5540003a87a9ce3309fa2a
https://serval.unil.ch/resource/serval:BIB_AA45A63A4CB1.P001/REF.pdf

12
In Silico prediction of the molecular basis of ClTx and AaCTx interaction with matrix metalloproteinase-2 (MMP-2) to inhibit glioma cell invasion

Authors: Othman, Houcemeddine, Wieninger, Silke Andrea, Elayeb, Mohamed, Nilges, Michael, Srairi-Abid, Najet

Contributors: Laboratoire des Venins et Biomolécules Thérapeutiques - Laboratory of Venoms and Therapeutic Biomolecules (LR11IPT08), Institut Pasteur de Tunis, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Université de Carthage - University of Carthage, Bioinformatique structurale - Structural Bioinformatics, Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), This work was supported by the Ministry of Research of Tunisia [reference number TOX11], project ACIP (Action concertée des instituts Pasteur) [reference number YC/MJ/KV/AS/ 50]., We thank Pr. José Luis (INSERM UMR 911-CRO2, Aix-Marseille, University, France) and Pr. Naziha Marrakchi (Laboratory of venoms and therapeutic biomolecules, Pasteur Institute of Tunis, Tunisia) for their helpful discussion and critical comments on the manuscript. We are also very grateful to Dr. Tru Huynh from the structural bioinformatics unit at Pasteur Institute of Paris for his valuable technical assistance.

Source: Journal of Biomolecular Structure and Dynamics
Journal of Biomolecular Structure and Dynamics, Taylor & Francis: STM, Behavioural Science and Public Health Titles, 2016, 28, pp.1-15. ⟨10.1080/07391102.2016.1231633⟩

Subject Terms: MMP-2, molecular modeling, glioblastoma, collagen binding domain, chlorotoxin, MESH: Arginine/metabolism, MESH: Binding Sites/drug effects, MESH: Molecular Dynamics Simulation, MESH: Neoplasm Invasiveness/pathology, MESH: Peptides/pharmacology, MESH: Protein Binding/drug effects, MESH: Scorpion Venoms/pharmacology, MESH: Brain Neoplasms/drug therapy, MESH: Brain Neoplasms/metabolism, MESH: Cell Line, Tumor, MESH: Computer Simulation, MESH: Glioma/drug therapy, MESH: Glioma/metabolism, MESH: Humans, MESH: Matrix Metalloproteinase 2/metabolism, [SDV]Life Sciences [q-bio], [SDV.CAN]Life Sciences [q-bio]/Cancer

Access URL: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::05be67513d03b1c9fb5956b352cf579a
https://hal-riip.archives-ouvertes.fr/pasteur-01452971

14
Brain targeting effect of camptothecin-loaded solid lipid nanoparticles in rat after intravenous administration

Authors: Cláudia Nunes, Salette Reis, Sandra Martins, Bruno Sarmento, Domingos Ferreira, Marlene Lúcio

Source: Martins, S M, Sarmento, B, Nunes, C, Lucio, M, Reis, S & Ferreira, D C 2013, ' Brain targeting effect of camptothecin-loaded solid lipid nanoparticles in rat after intravenous administration ', European Journal of Pharmaceutics and Biopharmaceutics, vol. 85, no. 3, part A, pp. 488-502 . https://doi.org/10.1016/j.ejpb.2013.08.011

Subject Terms: Pharmaceutical Science, General Medicine, Biotechnology, IC50, Chemistry, Pharmacokinetics, Cytotoxicity, Drug, media_common.quotation_subject, media_common, Solid lipid nanoparticle, Camptothecin, medicine.drug, medicine, Biochemistry, Glioma, medicine.disease, Biodistribution, Biophysics, Administration, Intravenous, Animals, Antineoplastic Agents, Phytogenic/administration & dosage, Blood-Brain Barrier/metabolism, Brain Neoplasms/drug therapy, Brain/metabolism, Camptothecin/administration & dosage, Cell Line, Drug Carriers/chemistry, Drug Delivery Systems, Glioma/drug therapy, Humans, Inhibitory Concentration 50, Lipids/chemistry, Macrophages/drug effects, Male, Nanoparticles, Particle Size, Rats, Rats, Wistar, Scattering, Small Angle, Tissue Distribution, neoplasms, heterocyclic compounds, polycyclic compounds

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ba4f22330b19390f779a2e9cbad6e1b
https://api.elsevier.com/content/article/PII:S0939641113002907?httpAccept=text/xml

15
challenges of intrinsic resistance and drug efflux

Authors: Lin, Fan, de Gooijer, Mark C, Hanekamp, Diana, Brandsma, Dieta, Beijnen, Jos H, van Tellingen, Olaf

Source: CNS Oncology. 2(3):271-88

Subject Terms: ATP-Binding Cassette Transporters/metabolism, Animals, Antineoplastic Agents/pharmacokinetics, Blood-Brain Barrier/drug effects, Brain Neoplasms/drug therapy, Clinical Trials as Topic, Drug Resistance, Neoplasm, Glioma/drug therapy, Humans, Molecular Targeted Therapy, nervous system diseases

Access URL: https://explore.openaire.eu/search/publication?articleId=dris___00893::0936d269b26ed3b1b1ac6e8edc1accfe

16
Global and regional brain glucose metabolism decline after systemic chemotherapy

Authors: Eivind Antonsen Segtnan, Saeid Gholami, Abass Alavi

Source: Gholami, S, Antonsen Segtnan, E & Alavi, A 2015, ' Global and regional brain glucose metabolism decline after systemic chemotherapy ', European Journal of Nuclear Medicine and Molecular Imaging, vol. 42, no. 6, pp. 981-983 . https://doi.org/10.1007/s00259-015-3023-8

Subject Terms: Radiology Nuclear Medicine and imaging, General Medicine, Positron emission tomography, medicine.diagnostic_test, medicine, White matter, medicine.anatomical_structure, Cerebral cortex, Standardized uptake value, Dementia, medicine.disease, business.industry, business, Nuclear medicine, Region of interest, Cancer, Internal medicine, medicine.medical_specialty, Basal ganglia, Endocrinology, Brain Neoplasms/drug therapy, Brain/diagnostic imaging, Fluorodeoxyglucose F18, Glucose/metabolism, Humans, Positron-Emission Tomography, Radiopharmaceuticals

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::134e44e1d51006420f1764b4ff1e9219
http://link.springer.com/content/pdf/10.1007/s00259-015-3023-8.pdf

PDF Full Text
17
Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan

Authors: Urup, Thomas, Dahlrot, Rikke Hedegaard, Grunnet, Kirsten, Christensen, Ib Jarle, Michaelsen, Signe Regner, Toft, Anders, Larsen, Vibeke Andrée, Broholm, Helle, Kosteljanetz, Michael, Hansen, Steinbjørn, Poulsen, Hans Skovgaard, Lassen, Ulrik

Source: Urup, T, Dahlrot, R H, Grunnet, K, Christensen, I J, Michaelsen, S R, Toft, A, Larsen, V A, Broholm, H, Kosteljanetz, M, Hansen, S, Poulsen, H S & Lassen, U 2016, ' Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan ', Acta Oncologica, vol. 55, no. 4, pp. 418-422 . https://doi.org/10.3109/0284186X.2015.1114679

Subject Terms: Medicine, Cell Biology, Biotechnology, Ecology, FOS: Biological sciences, Immunology, FOS: Clinical medicine, 69999 Biological Sciences not elsewhere classified, 19999 Mathematical Sciences not elsewhere classified, FOS: Mathematics, Cancer, Science Policy, Hematology, Plant Biology, Radiology Nuclear Medicine and imaging, Oncology, General Medicine, Multivariate analysis, Bevacizumab, medicine.drug, medicine, Internal medicine, medicine.medical_specialty, Young adult, Population, education.field_of_study, education, Cohort study, Proportional hazards model, Irinotecan, Retrospective cohort study, business.industry, business, Bioinformatics, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Bevacizumab/administration & dosage, Brain Neoplasms/drug therapy, Camptothecin/administration & dosage, Cohort Studies, Disease-Free Survival, Female, Follow-Up Studies, Glioblastoma/drug therapy, Humans, Male, Middle Aged, Models, Biological, Neoplasm Recurrence, Local/drug therapy, Prognosis, Retrospective Studies, Young Adult

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e50800861b88d6986aae2cc4c4470e3f

18
Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (EORTC 26082)

Authors: Wick, Wolfgang, Gorlia, Thierry, Bady, Pierre, Platten, Michael, van den Bent, Martin J, Taphoorn, Martin J B, Steuve, Jonathan, Brandes, Alba A, Hamou, Marie-France, Wick, Antje, Kosch, Markus, Weller, Michael, Stupp, Roger, Roth, Patrick, Golfinopoulos, Vassilis, Frenel, Jean-Sebastien, Campone, Mario, Ricard, Damien, Marosi, Christine, Villa, Salvador, Weyerbrock, Astrid, Hopkins, Kirsten, Homicsko, Krisztian, Lhermitte, Benoit, Pesce, Gianfranco, Hegi, Monika E

Source: Clinical Cancer Research
Wick, Wolfgang; Gorlia, Thierry; Bady, Pierre; Platten, Michael; van den Bent, Martin J; Taphoorn, Martin J B; Steuve, Jonathan; Brandes, Alba A; Hamou, Marie-France; Wick, Antje; Kosch, Markus; Weller, Michael; Stupp, Roger; Roth, Patrick; Golfinopoulos, Vassilis; Frenel, Jean-Sebastien; Campone, Mario; Ricard, Damien; Marosi, Christine; Villà, Salvador; Weyerbrock, Astrid; Hopkins, Kirsten; Homicsko, Krisztian; Lhermitte, Benoit; Pesce, Gianfranco; Hegi, Monika E (2016). Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (EORTC 26082). Clinical Cancer Research, 22(19):4797-4806.
Clinical Cancer Research, 22(19), 4797-4806
Clinical cancer research, vol. 22, no. 19, pp. 4797-4806
Clinical Cancer Research : An Official Journal of the American Association For Cancer Research 22(19) 4797-4806

Subject Terms: Clinic for Neurology, Clinic for Oncology and Hematology, 610 Medicine & health, Cancer Research, Oncology, Temsirolimus, medicine.drug, medicine, Phases of clinical research, Performance status, Internal medicine, medicine.medical_specialty, Surgery, Chemoradiotherapy, Temozolomide, Sirolimus, MGMT-Unmethylated Glioblastoma, Population, education.field_of_study, education, business.industry, business, Adult, Aged, Brain Neoplasms/drug therapy, Brain Neoplasms/mortality, Brain Neoplasms/radiotherapy, Chemoradiotherapy/methods, DNA Methylation, DNA Modification Methylases/genetics, DNA Repair Enzymes/genetics, Dacarbazine/administration & dosage, Dacarbazine/analogs & derivatives, Female, Glioblastoma/drug therapy, Glioblastoma/mortality, Glioblastoma/radiotherapy, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Promoter Regions, Genetic/genetics, Proportional Hazards Models, Sirolimus/administration & dosage, Sirolimus/analogs & derivatives, Tumor Suppressor Proteins/genetics, Young Adult

File Description: application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9d7fef0d1608d3697456d8fd4775b80

19
The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells

Authors: Hosein, Abdel Nasser, Lim, Yi Chieh, Day, Bryan, Stringer, Brett, Rose, Stephen, Head, Richard, Cosgrove, Leah, Sminia, Peter, Fay, Michael, Martin, Jennifer H

Contributors: Hosein, Abdel Nasser, Lim, Yi Chieh, Day, Bryan, Stringer, Brett, Rose, Stephen, Head, Richard, Cosgrove, Leah, Sminia, Peter, Fay, Michael, Martin, Jennifer H, Radiation Oncology, CCA - Cancer biology and immunology, CCA - Target Discovery & Preclinial Therapy Development

Source: Journal of Neuro-Oncology, 122(2), 263-271. Kluwer Academic Publishers

Subject Terms: glioblastoma, valproic acid, radiosensitisation, Animals, Antineoplastic Agents/administration & dosage, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Brain Neoplasms/drug therapy, Cell Survival/drug effects, Cells, Cultured, Chemoradiotherapy/methods, DNA Methylation, DNA Modification Methylases/genetics, DNA Repair Enzymes/genetics, Dacarbazine/administration & dosage, Dose-Response Relationship, Drug, Gene Expression Profiling, Glioblastoma/drug therapy, Humans, Mice, Inbred NOD, Mice, SCID, Microarray Analysis, Neoplasm Transplantation, Promoter Regions, Genetic, Radiation-Sensitizing Agents/administration & dosage, Tumor Suppressor Proteins/genetics, Valproic Acid/administration & dosage, Cancer Research, Clinical Neurology, Neurology, Oncology, Valproic Acid, medicine.drug, medicine, Pharmacology, DNA methylation, In vitro, In vivo, business.industry, business, Temozolomide, Gene expression profiling, Microarray analysis techniques, Dose–response relationship, Cells, Cultured, Dose-Response Relationship, Drug, Mice, Inbred NOD, SCID, Promoter Regions, Genetic, lipids (amino acids, peptides, and proteins)

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d598ba1e81a0fbe29ea450812f16d6a

20
Dexamethasone Destabilizes Nmyc to Inhibit the Growth of Hedgehog-Associated Medulloblastoma

Authors: Jason Ling, Vivi M. Heine, David H. Rowitch, Markus Priller, Ulrich Schüller

Contributors: Pediatrics

Source: Cancer Research, 70(13), 5220-5. American Association for Cancer Research Inc.

Subject Terms: Cancer Research, Oncology, Hedgehog signaling pathway, Medulloblastoma, medicine.disease, medicine, Cell signaling, Smoothened, Internal medicine, medicine.medical_specialty, GSK-3, Endocrinology, Sonic hedgehog, biology.protein, biology, Cell biology, Genetically modified mouse, Hedgehog, Animals, Brain Neoplasms/drug therapy, Dexamethasone/pharmacology, Glycogen Synthase Kinase 3/metabolism, Glycogen Synthase Kinase 3 beta, Hedgehog Proteins/antagonists & inhibitors, Medulloblastoma/drug therapy, Mice, Transgenic, Phosphorylation, Protein Structure, Tertiary, Proto-Oncogene Proteins c-myc/antagonists & inhibitors, Signal Transduction, Tumor Cells, Cultured, Article, Mice, Transgenic, Protein Structure, Tertiary, Tumor Cells, Cultured, hormones, hormone substitutes, and hormone antagonists, polycyclic compounds, embryonic structures, animal structures, endocrine system

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::087c06958028b3f881ec566c21c4bcc8
https://syndication.highwire.org/content/doi/10.1158/0008-5472.CAN-10-0554

Search Tools: Get RSS Feed — Email this Search